← All trials
NCT00525408
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2007
- Primary completion
- Jan 1, 2013
- Completion date
- Jan 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 134
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cadila HealthcareLead sponsor
- Chatrapati Sahuji Mahraj Medical UniversityOverall official - principal investigator
- Safdarjang HospitalOverall official - principal investigator
- Kasturba Medical CollegeOverall official - principal investigator
- LTMMC & LTMGHOverall official - principal investigator
- RCC, TrivandrumOverall official - principal investigator
- Patel Hospital Pvt. Ltd.Overall official - principal investigator
- Kidwai Memorial Institute of Oncology, BangaloreOverall official - principal investigator
- Postgraduate Institute of Medical Education and ResearchOverall official - principal investigator
- Choithram Hospital and Research CentreOverall official - principal investigator
- Rajiv Gandhi University of Health SciencesOverall official - principal investigator
- Seth Gordhandas Sunderdas Medical CollegeOverall official - principal investigator
- Christian Medical College, Vellore, IndiaOverall official - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.